The overview of modern approaches in treatment of triple negative breast cancer

Abstract

By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer.

Antitumor efficacy of liposomal doxorubicin hydrochloride in combination with tamoxifen. Experimental study

“…use adjuvant chemotherapy to achieve several goals: reducing the volume of the primary tumor; reducing the size and number of affected lymph nodes; increase in the number of conservative surgical interventions; elimination of distant micrometastases, etc. [3,6,7].…”